Cargando…
Targeting the receptor tyrosine kinase RET in combination with aromatase inhibitors in ER positive breast cancer xenografts
The majority of breast cancers are estrogen receptor positive (ER+). Blockade of estrogen biosynthesis by aromatase inhibitors (AIs) is the first-line endocrine therapy for post-menopausal women with ER+ breast cancers. However, AI resistance remains a major challenge. We have demonstrated previousl...
Autores principales: | Andreucci, Elena, Francica, Paola, Fearns, Antony, Martin, Lesley-Ann, Chiarugi, Paola, Isacke, Clare M., Morandi, Andrea |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5348339/ https://www.ncbi.nlm.nih.gov/pubmed/27602955 http://dx.doi.org/10.18632/oncotarget.11826 |
Ejemplares similares
-
Targeting RET–interleukin-6 crosstalk to impair metastatic dissemination in breast cancer
por: Morandi, Andrea, et al.
Publicado: (2014) -
RET Receptor Tyrosine Kinase: Role in Neurodegeneration, Obesity, and Cancer
por: Mahato, Arun Kumar, et al.
Publicado: (2020) -
Ret receptor tyrosine kinase sustains proliferation and tissue maturation in intestinal epithelia
por: Perea, Daniel, et al.
Publicado: (2017) -
Binding of EphrinA5 to RET receptor tyrosine kinase: An in vitro study
por: Liu, Yixin, et al.
Publicado: (2018) -
Plasma receptor tyrosine kinase RET in pulmonary arterial hypertension diagnosis and differentiation
por: Säleby, Joanna, et al.
Publicado: (2019)